Abstract

Retinal thickness may serve as a biomarker in Parkinson’s disease (PD). In this prospective longitudinal study, we aimed to determine if PD patients present accelerated thinning rate in the parafoveal ganglion cell-inner plexiform layer (pfGCIPL) and peripapillary retinal nerve fiber layer (pRNFL) compared to controls. Additionally, we evaluated the relationship between retinal neurodegeneration and clinical progression in PD. A cohort of 156 PD patients and 72 controls underwent retinal optical coherence tomography, visual, and cognitive assessments between February 2015 and December 2021 in two Spanish tertiary hospitals. The pfGCIPL thinning rate was twice as high in PD (β [SE] = −0.58 [0.06]) than in controls (β [SE] = −0.29 [0.06], p < 0.001). In PD, the progression pattern of pfGCIPL atrophy depended on baseline thickness, with slower thinning rates observed in PD patients with pfGCIPL below 89.8 µm. This result was validated with an external dataset from Moorfields Eye Hospital NHS Foundation Trust (AlzEye study). Slow pfGCIPL progressors, characterized by older at baseline, longer disease duration, and worse cognitive and disease stage scores, showed a threefold increase in the rate of cognitive decline (β [SE] = −0.45 [0.19] points/year, p = 0.021) compared to faster progressors. Furthermore, temporal sector pRNFL thinning was accelerated in PD (βtime x group [SE] = −0.67 [0.26] μm/year, p = 0.009), demonstrating a close association with cognitive score changes (β [SE] = 0.11 [0.05], p = 0.052). This study suggests that a slower pattern of pfGCIPL tissue loss in PD is linked to more rapid cognitive decline, whereas changes in temporal pRNFL could track cognitive deterioration.

Details

Title
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Author
Murueta-Goyena, Ane 1   VIAFID ORCID Logo  ; Romero-Bascones, David 2 ; Teijeira-Portas, Sara 3 ; Urcola, J. Aritz 4 ; Ruiz-Martínez, Javier 5 ; Del Pino, Rocío 6   VIAFID ORCID Logo  ; Acera, Marian 6 ; Petzold, Axel 7   VIAFID ORCID Logo  ; Wagner, Siegfried Karl 8 ; Keane, Pearse Andrew 8 ; Ayala, Unai 9   VIAFID ORCID Logo  ; Barrenechea, Maitane 9   VIAFID ORCID Logo  ; Tijero, Beatriz 10 ; Gómez Esteban, Juan Carlos 11   VIAFID ORCID Logo  ; Gabilondo, Iñigo 12   VIAFID ORCID Logo 

 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000 0001 2167 1098) 
 Biomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Mondragón, Spain (GRID:grid.436417.3) (ISNI:0000 0001 0662 2298); NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837) 
 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.439257.e) 
 Araba University Hospital, Department of Ophthalmology, Vitoria-Gasteiz, Spain (GRID:grid.439257.e) 
 Donostia University Hospital, Department of Neurology, Donostia, Spain (GRID:grid.414651.3) (ISNI:0000 0000 9920 5292); Biogipuzkoa Health Research Institute, Donostia, Spain (GRID:grid.414651.3); CIBERNED, Institute of Health Carlos III, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.413448.e) 
 NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837); University College London, Queen Square Institute of Neurology, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201); The National Hospital for Neurology and Neurosurgery, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631); Amsterdam UMC, Departments of Neurology and Ophthalmology, Amsterdam, Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010) 
 NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837); University College London, Institute of Ophthalmology, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201) 
 Biomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Mondragón, Spain (GRID:grid.436417.3) (ISNI:0000 0001 0662 2298) 
10  Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.436417.3); Cruces University Hospital, Neurology Department, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135) 
11  Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.411232.7); Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000 0001 2167 1098); Cruces University Hospital, Neurology Department, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135) 
12  Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.411232.7); Cruces University Hospital, Neurology Department, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135); IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain (GRID:grid.424810.b) (ISNI:0000 0004 0467 2314) 
Pages
26
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2917706644
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.